Sogle net treatment for heart failure results released heavy! How many surprises are there about SGLT2 inhibitors?

According to the International Diabetes Federation (IDF), about 463 million adults worldwide will have diabetes in 2019, and the number of people with diabetes is expected to reach 700 million by 2045.
Although the diabetes treatment market is highly competitive, there is still unseeded demand in the diabetes treatment market as diabetes prevalence increases and the development of complications, especially for treatments that offer both blood sugar and non-glucose benefits.
In recent years, one of the priorities of diabetes drug development has been the search for drugs with cardiovascular (CV) benefits, where glutatrogen-like peptide-1 (GLP-1) peptides and sodium-glucose co-transport protein 2 (SGLT2) inhibitors have developed rapidly, especially SGLT2 inhibitors have been surprising drug developers and are still emerging! "Cross-border" treatment of heart failure! Sogley Net Research Weight release November 13-17, local time, the 93rd American Heart Association Scientific Annual Meeting (AHA 2020) held online, the meeting released Sogrin net treatment of diabetes combined with compensation heart failure patients with the latest study SOLOIST-WHF.
sotagliflozin molecular structure SOLOIST-WHF trial is a phase III, double-blind, randomized, placebo-controlled trial.
the trial was originally designed as the primary endpoint of the first cardiovascular death or hospitalization for heart failure, which was later changed to the total number of patients hospitalized for heart failure and emergency care.
previous clinical trials of SGLT2 inhibitor drugs for secondary prevention of heart failure focused mainly on patients with type 2 diabetes or confirmed heart failure but stable symptoms of heart failure, and few SGLT2 inhibitors were studied in patients with a paid attack of heart failure.
the study pushed SGLT2 inhibitors' adaptation to heart failure treatment to patients with recent worsening heart failure.
results showed that Sogle net can absolutely reduce the rate of major endpoint events in adult patients by 25.3%, with a relative decrease rate of 33.2%.
results add new clinical evidence to the treatment of heart failure with SGLT2 inhibitors.
In addition, in the subgroup analysis, it was also seen that whether the heart failure (HFpEF) retained for the shot fraction or the heart failure (HFrEF) of the shot fraction was reduced, the application of Sogle net reduced the occurrence of end events, but was more effective in HFpEF patients (HR:0.48 vs 0.72), providing new ideas for HFpEF treatment.
has been approved by the European Union for Type 1 disease, but has not yet been put into use, and the FDA has rejected the species' listing application.
Last year, Sanofi abandoned the Sogle net development project, and while it may be too late for Lexicon to win the SOLOIST trial, the trial suggests that Sanofi net is good for heart failure patients with shot fraction retention and may be good news for other SGLT2 inhibitor competitors.
results from the AHA 2020 report came from a truncated version of the trial and the endpoint was changed, and the results were evaluated by researchers rather than independent agencies, and given that HFpEF treatment has been difficult to break through, there is reason to be cautious about the results.
, however, the potential of these drugs will soon become clear, with the release next year of research data from Lilly/Brigingham's Jardiance and AstraZeneven's Farxiga HFpEF.
SGLT2 inhibitors are constantly surprised! Several domestic companies initially approved SGLT2 inhibitors for type 2 diabetes, while in 2019 three SGLT2 inhibitors were approved in Europe and Japan for type 1 diabetes patients: AstraZeneca's Dapagliflozin, Astellas' Suglat and Lexicon's Zynquista.
the sugar-lowering effects of SGLT2 inhibitors are significant, the cardiovascular benefits of these drugs are also of great concern.
2019 ESC Diabetes Guidelines use SGLT2 inhibitors as the primary recommended drug for diabetes combined with cardiovascular high risk/extremely high risk patients (recommended level I A); The Clinical Practice Guide for Diabetic Nephropathy and the 2020 KDIGO Clinical Practice Guide: Diabetes Management in Patients with Chronic Kidney Disease clearly recommend SGLT2 inhibitors as international guidelines for first-line drug use in patients with diabetic nephropathy (DKD).
, SGLT2 inhibitors may provide new targets for HFpEF treatments.
currently listed a number of SGLT2 inhibitors, there are Dagle net, Kagele net, Engele net, Agle net 4 kinds, mainly imports, but Kagle net and Ingre net has been generic drugs listed.
For the development of SGLT2 inhibitors, there are also a number of varieties into the clinical, which entered Phase III clinical trials in Jiangsu Hengrui Hengle net, Shandong Xuanzhu medicine's Gagle net, Guangdong Dongsian's Ronggre net.
: In recent years, significant progress has been made in the field of diabetes, but there are still many unsealed clinical needs for diabetes treatment.
the most fundamental need for diabetes treatment is to develop breakthrough therapies to address the impact of the disease on the lives of patients, and while it remains to be seen whether a real treatment can be found and developed, there are certainly some treatments in the pipeline that promise to address the disease."
While the SOLOIST-WHF findings are not rigorous enough, the potential of such drugs will soon become clear as Lilly/Blingeringham's Jardiance and AstraZeneven's Farxiga's HFpEF research data are released next year.